• 95. Modality convergence in advanced therapies

  • Oct 24 2024
  • Length: 20 mins
  • Podcast

95. Modality convergence in advanced therapies

Listen for free

View show details

  • Summary

  • Join us as Dr. Aravind Asokan from Duke University explores cutting-edge technologies revolutionizing advanced therapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges, discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future of disease treatment.

    This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-like particles (VLPs).


    Show notes:

    Asokan A, et al. ‘An evolved AAV variant enables efficient genetic engineering of murine T cells’. Cell. 2023 Jan 19;186(2):446-460. https://doi.org/10.1016/j.cell.2022.12.022


    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about 95. Modality convergence in advanced therapies

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available